78 results
6-K
EX-99.1
LMNL
Liminal BioSciences Inc.
2 May 23
Notice of Annual Meeting of Shareholders
4:19pm
to the Board on a continuous and frequent basis in respect of any material developments, updated business strategy, as well as to provide regular … to drive both short-term and long-term performance and the right talent in the right roles to execute on the Company's business strategy. While the Company's
6-K
EX-99.3
LMNL
Liminal BioSciences Inc.
9 Nov 22
Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights
4:11pm
and assets that were no longer part of its core strategy. In addition, the Company has also entered into a termination agreement for the settlement
6-K
EX-99.1
LMNL
Liminal BioSciences Inc.
13 Sep 22
Current report (foreign)
7:06am
development with a cash runway sufficient to achieve these goals. Value Creation Strategy Aimed at Best or First in Class Drug Discovery & Development
6-K
EX-99.3
LMNL
Liminal BioSciences Inc.
10 Aug 22
Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights
12:00am
purchase agreement(s), or SPA(s), in 2021 for the sale of businesses and assets that were no longer part of its core strategy and continues to take steps
6-K
EX-99.1
LMNL
Liminal BioSciences Inc.
24 May 22
Current report (foreign)
8:55am
to achieve these goals. Value Creation Strategy Aimed at Both Best or First in Class Drug Discovery & Development
The conjugation of fezagepras
6-K
EX-99.3
nyx9kylfh8 sg0e
10 May 22
Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights
4:55pm
6-K
EX-99.1
md66h9 wf9
3 May 22
Notice of Annual Meeting of Shareholders
8:32am
6-K
EX-99.1
k8achb0oc8c3
16 Feb 22
Current report (foreign)
7:46am
6-K
EX-99.1
17emj29v 6d
19 Jan 22
Liminal BioSciences Announces Strategic Priorities For 2022
4:56pm
6-K
EX-99.2
4b76nul4bfknp6
16 Nov 21
Liminal BioSciences Reports Third Quarter 2021 Financial Results
12:00am
6-K
EX-99.1
80ki8k 3fp
16 Nov 21
Liminal BioSciences Reports Third Quarter 2021 Financial Results
12:00am
6-K
EX-99.1
8by9uox8 zz82
28 Sep 21
Liminal BioSciences Announces Closing of Sale of Priority Review Voucher
4:25pm
6-K
EX-99.2
v89qi5s swxleg8h6
16 Aug 21
Liminal BioSciences Reports Second Quarter 2021 Financial Results
5:08pm
6-K
EX-99.1
mcdkjt7
16 Aug 21
Liminal BioSciences Reports Second Quarter 2021 Financial Results
5:08pm
6-K
EX-99.1
84wt 45efy91
25 Jun 21
Form 51 102F3 Material Change Report
4:35pm
6-K
EX-99.1
h6oll2qg phdw
23 Jun 21
Liminal Biosciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion
8:35am
6-K
EX-99.1
0oswtp1o
4 Jun 21
Current report (foreign)
4:35pm
6-K
EX-99.1
9sgkxilqax cp5oyaeg
17 May 21
Liminal BioSciences Reports First Quarter 2021 Financial Results
5:11pm
6-K
EX-99.2
71fo8
17 May 21
Liminal BioSciences Reports First Quarter 2021 Financial Results
5:11pm